NCT00738764 is a Phase 1 clinical trial of PDL192 in Cancer, sponsored by Abbott.

Who is sponsoring NCT00738764?

NCT00738764 is sponsored by Abbott.

What drugs are being tested in NCT00738764?

Interventions in NCT00738764: PDL192.

Is NCT00738764 still recruiting?

NCT00738764 is currently completed. Last updated 5 January 2012.

Last reviewed 2012-01-05 · How we verify

NCT00738764

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects With Advanced Solid Tumors

Completed Phase 1 Last updated 5 January 2012

What this trial tests

Phase 1 trial testing PDL192 in Cancer in 30 participants. Completed in 1 October 2011.

Timeline

1 July 2008

Primary endpoint
1 October 2011

1 October 2011

Quick facts

Lead sponsor	Abbott
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 July 2008
Primary completion	1 October 2011
Estimated completion	1 October 2011
Sites	2 locations across United States

Drugs / interventions tested

PDL192 — full drug profile →

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

Abbott — full company profile →

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Maximum tolerated dose
Time frame: after four weeks of dosing

Sponsor's own description

This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Principles of antibody-mediated TNF receptor activation.
Wajant H. · · 2015 · cited 111× · PMID 26292758 · DOI 10.1038/cdd.2015.109
TWEAK and the progression of renal disease: clinical translation.
Sanz AB, Izquierdo MC, Sanchez-Niño MD, Ucero AC, et al · · 2014 · cited 86× · PMID 24493870 · DOI 10.1093/ndt/gft342
Muscle Wasting Diseases: Novel Targets and Treatments.
Furrer R, Handschin C. · · 2019 · cited 75× · PMID 30148697 · DOI 10.1146/annurev-pharmtox-010818-021041
The TWEAK-Fn14 system as a potential drug target.
Wajant H. · · 2013 · cited 71× · PMID 23957828 · DOI 10.1111/bph.12337
TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic.
Cheng E, Armstrong CL, Galisteo R, Winkles JA. · · 2013 · cited 45× · PMID 24391646 · DOI 10.3389/fimmu.2013.00473
TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
Cordido A, Nuñez-Gonzalez L, Martinez-Moreno JM, Lamas-Gonzalez O, et al · · 2021 · cited 34× · PMID 34155062 · DOI 10.1681/asn.2020071094
TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure.
Novoyatleva T, Sajjad A, Engel FB. · · 2014 · cited 29× · PMID 24611063 · DOI 10.3389/fimmu.2014.00050
A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo.
Trebing J, Lang I, Chopra M, Salzmann S, et al · · 2014 · cited 24× · PMID 24135629 · DOI 10.4161/mabs.26709

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Abbott trials

Trials by the same sponsor.

NCT06217393 — Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia · Phase 3 · completed
NCT05370703 — A Clinical Study to Evaluate the Effect of Mobile Applications "My A:Care" and "Smart Coach" on the Lipid-lowering Treat · completed
NCT05519514 — Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects · Phase 1 · completed
NCT04784208 — A Study to Determine the Validity and Sensitivity of 'Questionnaire to Screen for HYpothyroidism' (Q'SHY) · unknown
NCT05175131 — Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00738764 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abbott
Last refreshed: 5 January 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00738764.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing